Why is Glaxosmi. Pharma falling/rising?

As of 06-Aug, Glaxosmithkline Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 2,711.85, which represents a decrease of 128.45 points or 4.52%. The stock has been underperforming, having lost 15.12% over the past week and 17.50% over the past month. It has also touched an intraday low of Rs 2,659, indicating a significant drop of 6.38%. The stock has been on a consecutive downward trend for the last five days, and its performance today has underperformed the sector by 2.46%. Despite having a high management efficiency with a return on equity (ROE) of 42.32% and a low debt-to-equity ratio, the recent price movement reflects negative sentiment among investors, as evidenced by a decrease in delivery volume.
In the broader market context, the stock's recent performance contrasts sharply with the benchmark Sensex, which has only fallen by 1.15% over the past week. The pharmaceuticals and drugs sector as a whole has also declined by 2.06%, indicating a challenging environment for the industry. While Glaxosmithkline Pharmaceuticals has shown strong year-to-date returns of 20.70%, the recent downturn suggests that short-term pressures are outweighing long-term gains. The falling investor participation and liquidity issues further exacerbate the stock's struggles in the current market climate.